Latest equities thinking
-
Bank securities: Unloved, but why?
16 Feb 2023
Oliver Judd and Betty Sanchez Torres argue that despite a recovery in prices, banking sector securities continue to offer value so long as a deeper recession is avoided.
-
Bear rallies and bucket lists: Navigating UK equities in 2023
14 Feb 2023
Despite hopes inflation will be brought back under control and that the prospects for the UK economy might not be as gloomy as feared, Charlotte Meyrick and Trevor Green explain why equity investors must remain disciplined in 2023.
-
Follow the leader: Why companies should take the drama out of CEO succession planning
19 Jan 2023
Botched leadership handovers can severely impair company performance. To satisfy investors, boards need to take succession planning more seriously, argue Trevor Green and Louise Piffaut.
-
Charging up: Batteries and the fight against climate change
5 Jan 2023
Batteries are set to play a crucial role in helping to decarbonise the global transport and energy sectors. As capital floods into an industry experiencing exponential growth, we look at the key considerations for investors.
-
Global equity income Q&A: Richard Saldanha on dividends and downturns
28 Oct 2022
In a challenging economic environment, where can income investors find companies that can grow and sustain dividends? Richard Saldanha answers the big questions.
-
The ‘Hotel California’ effect: Why equity investors should keep an eye on switching costs
13 Oct 2022
Companies whose customers face barriers to exit often deliver more resilient performance over the long term, says Francois de Bruin.
-
UK equities: Truss, takeovers and turbulence
11 Oct 2022
Charlotte Meyrick and Trevor Green discuss the key narratives driving UK equities and where they see opportunities amidst a challenging backdrop.
-
Zero-COVID: China’s costly policy error
10 Aug 2022
Beijing’s ideological battle to stamp out COVID-19 appears increasingly misguided as the rest of the world learns to live with the virus. But the impact of China’s approach will be felt far beyond its borders.
-
Supply chains, painkillers and gene editing: ESG risks in pharma
29 Jun 2022
Reflecting on ESG risks in the pharmaceutical industry, Sora Utzinger discusses supply chains and counterfeit medicines, access to painkillers, and the ethics of gene editing.
-
UK Equities: Five questions with Charlotte Meyrick and Trevor Green
14 Jun 2022
Charlotte Meyrick and Trevor Green explain why 2022 has all been about getting your sector calls right in UK equities.
Discover our equities capabilities
Select from a broad range of actively managed funds focusing on growth, income or a combination of both from a variety of geographies and sectors.
Subscribe to AIQ
Receive our insights on the big themes influencing financial markets and the global economy, from interest rates and inflation to technology and environmental change.